BioLife Solutions reported strong revenue growth and increased financial guidance, driven by cell processing revenue and strategic investments. However, increased operating expenses and a decrease in gross margin led to a higher net loss. Despite these challenges, the company's strong performance in revenue growth and strategic positioning suggest a positive outlook.

Company Guidance

During the BioLife Solutions Q2 2025 conference call, the company announced an increase in their full-year revenue guidance, reflecting confidence in sustained growth driven by a 28% year-over-year increase in cell processing revenue for the quarter. Total revenue for Q2 2025 rose by 29% to $25.4 million, with adjusted EBITDA margin expanding by 400 basis points to 24%. The company maintains a strong financial position with over $100 million in cash and marketable securities, enabling strategic investments like the recent stake in Pluristyx. BioLife's biopreservation media (BPM) product line, which represents about 85% of Q2 cell processing revenue, continues to be a key growth driver, embedded in 16 approved therapies and over 250 commercially sponsored CGT trials in the U.S. The company raised its full-year cell processing revenue guidance to $91 million to $93 million, representing a 24% to 26% increase over 2024, while total revenue is projected to reach $100 million to $103 million, up 22% to 25%. Despite broader macroeconomic uncertainties, BioLife is optimistic about capturing more market share and advancing its product portfolio.

Strong Revenue Growth

BioLife Solutions reported Q2 revenue of $25.4 million, marking a 29% year-over-year increase. This growth was driven by a 28% increase in cell processing revenue.

Increased Revenue Guidance

The company raised its full-year revenue guidance for 2025 to $100 million to $103 million, indicating a 22% to 25% growth over the previous year.

Improved Adjusted EBITDA

Adjusted EBITDA for Q2 2025 was $6.1 million or 24% of revenue, up from $3.9 million or 20% in the prior year, showing improved profitability.

Cell Processing Revenue Growth

Cell processing revenue reached $23 million, representing a 28% year-over-year increase and a 6% sequential increase.

Strategic Investment in Pluristyx

BioLife made a strategic investment in Pluristyx, a local early-stage, revenue-generating developer of iPSC-based products, aligning with BioLife's interest in expanding its product portfolio.

BioLife Solutions (BLFS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BLFS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.01 / -	-0.04	―	―	―
Aug 07, 2025	2025 (Q2)	-0.03 / -0.33	-0.16	-106.25% (-0.17)	―
May 08, 2025	2025 (Q1)	-0.05 / -0.01	-0.22	95.45% (+0.21)	―
Mar 03, 2025	2024 (Q4)	-0.06 / -0.04	-0.3	86.67% (+0.26)	―
Nov 12, 2024	2024 (Q3)	-0.08 / -0.04	-0.67	94.03% (+0.63)	―
Aug 08, 2024	2024 (Q2)	-0.14 / -0.16	-0.23	30.43% (+0.07)	―
May 09, 2024	2024 (Q1)	-0.31 / -0.22	-0.32	31.25% (+0.10)	―
Feb 29, 2024	2023 (Q4)	-0.34 / -0.30	-1.15	73.91% (+0.85)	―
Nov 09, 2023	2023 (Q3)	-0.38 / -0.67	-0.23	-191.30% (-0.44)	―
Aug 08, 2023	2023 (Q2)	-0.21 / -0.23	-1.71	86.55% (+1.48)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BLFS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$20.64	$22.68	+9.88%
May 08, 2025	$22.36	$23.29	+4.16%
Mar 03, 2025	$24.00	$24.51	+2.13%
Nov 12, 2024	$26.50	$24.11	-9.02%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioLife Solutions (BLFS) report earnings?

BioLife Solutions (BLFS) is schdueled to report earning on Nov 06, 2025, Before Open (Confirmed).

What is BioLife Solutions (BLFS) earnings time?

BioLife Solutions (BLFS) earnings time is at Nov 06, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BLFS EPS forecast?

BLFS EPS forecast for the fiscal quarter 2025 (Q3) is -0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing